Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
CONCLUSION: Patients who achieve an American College of Rheumatology target sUA below 6 mg/dL during ULT have higher rates of eGFR improvement, especially in CKD Stages 2 and 3.
PMID: 30201087 [PubMed - in process]
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Kidney Disease | Dialysis | Epidemiology | General Medicine | Rheumatology | Study | Urology & Nephrology